share_log

BRIEF-Rocket Pharmaceuticals Receives EMA Priority Medicines Designation For RP-L201 Gene Therapy

路透社 ·  Mar 29, 2021 21:11
March 29 (Reuters) - Rocket Pharmaceuticals Inc :
   * ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
   * ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment